AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019
24 Sep 2019
Small Cap Feast
Symphony Environmental Technologies plc (SYM:LON), 3.2 | Animalcare Group PLC (ANCR:LON), 217 | Moss Bros Group (MOSB:LON), 0 | GETECH Group plc (GTC:LON), 8.2 | Workspace Group PLC (WKP:LON), 490 | Silence Therapeutics plc (SLNCF:OTC), 0 | Allied Minds PLC (ALLWF:OTC), 0 | Biodexa Pharmaceuticals plc Sponsored ADR (BDRX:NAS), 0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Small Cap Feast
Symphony Environmental Technologies plc (SYM:LON), 3.2 | Animalcare Group PLC (ANCR:LON), 217 | Moss Bros Group (MOSB:LON), 0 | GETECH Group plc (GTC:LON), 8.2 | Workspace Group PLC (WKP:LON), 490 | Silence Therapeutics plc (SLNCF:OTC), 0 | Allied Minds PLC (ALLWF:OTC), 0 | Biodexa Pharmaceuticals plc Sponsored ADR (BDRX:NAS), 0
- Published:
24 Sep 2019 -
Author:
Derren Nathan - Pages:
AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019